Cardiologists Dr. Seth Baum and Dr. Michael Koren discuss the newly released top-line results from a big Lp(a) study investigating the effects of the drug pelacarsen. They talk about what Lp(a) is, why it matters, happened in the study, and what this means for other pelacarsen and Lp(a) studies worldwide. They take a deep dive into some of the factors that can reduce the effectiveness of clinical trials and explain that this particular failure doesn't undermine the theory behind controlling Lp(a) levels or the potential effectiveness of competing investigational medications. Finally, the companion cardiologists talk about what this means for people who have high Lp(a) and what they can do to help control their risks of associated heart problems.
Podden och tillhörande omslagsbild på den här sidan tillhör
Dr. Michael Koren. Innehållet i podden är skapat av Dr. Michael Koren och inte av,
eller tillsammans med, Poddtoppen.
